Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC has experienced a notable stock increase of approximately 22%, driven by promising developments surrounding its candidate GH001 for the treatment of Treatment-Resistant Depression (TRD), characterized by short clinical duration, rapid and durable efficacy, and favorable safety profiles. The recent lifting of the FDA's clinical hold on GH001 allows the company to advance towards a global Phase 3 program, with analysts projecting a potential market opportunity exceeding $1.4 billion at peak in TRD, in addition to anticipated revenues from other indications. Expectations surrounding GH001's pricing have been adjusted upward, reflecting confidence in its competitive advantages compared to existing treatments, positioning the company for significant financial growth and market penetration.

Bears say

GH Research PLC faces significant risks and uncertainties that contribute to a negative outlook on its stock. Key concerns include potential delays in progressing to Phase III trials due to regulatory challenges, unexpected safety signals, and failures in achieving sufficient efficacy, which could jeopardize the company's ability to commercialize its product candidates GH001 and GH002. Additionally, the absence of revenue generation, the complexities of developing neuropsychiatric treatments, and the competitive landscape further heighten the risks surrounding GH Research's financial stability and market viability.

GHRS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.